Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Transcript Expression
50%
Transcription Initiation
50%
SNRPN
50%
Late-stage Cancer
50%
Imprinting Center
50%
RNA Polymerase II (RNAPII)
50%
MRNA 3′ End Processing
50%
Histone H3 Lysine 27
50%
Small nuclear Ribonucleoprotein (snRNP)
50%
Multifocal Disease
50%
ABCC11
50%
Earwax
50%
Human Promoter
50%
GRB10
50%
Molecular Heterogeneity
50%
Melanoma Brain Metastases
50%
Molecular Tumor Board
37%
Normal Urothelium
33%
RNA Exosome
25%
Eukaryotic Genomes
25%
Activity-dependent Gene Expression
25%
Tiling Microarray
25%
Regulatory Potential
25%
DNA Methyltransferase 3B (DNMT3B)
25%
Differentially Methylated Regions
25%
Transcriptome Map
25%
TFIIB
25%
UV Treatment
25%
UV Analysis
25%
Mammalian Proteins
25%
Downstream Genes
25%
Promoter Binding
25%
Gene Activity
25%
Polyadenylation Sites
25%
Polycomb Group (PcG) Proteins
21%
Tumorigenic Transformation
16%
Acquired mutations
16%
Low-frequency mutation
16%
Deep Resequencing
16%
Intratumor
16%
CheckMate
16%
Transcription Cycle
12%
3′ End Processing
12%
Readthrough
12%
Gene Body
12%
3′ End Formation
12%
Functional Coupling
12%
RNA Maturation
12%
End-stage Cancer
12%
Druggability
12%
Biochemistry, Genetics and Molecular Biology
Exome Sequencing
66%
Methylation
50%
Single Nucleotide Polymorphism
50%
Mouse
50%
Allele
50%
Small Nuclear Ribonucleoprotein Polypeptide N
50%
Transcriptomics
50%
Mutation Rate
50%
DNA Methylation
50%
Histone H3
50%
Gene Mutation
50%
Cancer Staging
50%
Overall Survival
50%
Differentially Methylated Regions
37%
Angelman Syndrome
37%
Germ Cell
37%
Germline
25%
Intron
25%
Enhancer Region
25%
RNA Polymerase II
20%
Clinical Trial
16%
RNA Sequence
16%
Multivariate Analysis
16%
Polycomb-Group Proteins
15%
Exon
12%
Gene Polymorphism
12%
Genotyping
12%
Haplotype
12%
Cis Acting Element
12%
Nerve Cell Culture
12%
Somatic Cell
12%
Promoter Region
12%
RNA Degradation
12%
Transcription Termination
8%
Globin Gene
8%
DNMT3B
5%
DAP (Gene)
5%
Gene Activity
5%
Glial Cells
5%
Brain Cell Culture
5%
Medicine and Dentistry
Personalized Medicine
100%
Cancer Staging
100%
Targeted Therapy
100%
Neoplasm
74%
Diseases
50%
Bladder Cancer
50%
Malignant Neoplasm
37%
Clinical Trial
30%
Lung Cancer
18%
Overall Survival
16%
Tumour Heterogeneity
14%
Exome Sequencing
12%
Prostate Cancer
12%
Tumor Biopsy
12%
Biological Marker
12%
Molecular Profiling
12%
Gene Mutation
7%
Recurrent Disease
7%
Transcriptomics
7%
Mutation Rate
7%
Lymph Node Metastasis
7%
Hazard Ratio
5%
RNA Sequence
5%
Multivariate Analysis
5%
Adenocarcinoma
5%
